Top

Published in:

01-09-2009 | Case Report

Successful treatment with rituximab of refractory idiopathic thrombocytopenic purpura in a patient with Kabuki syndrome

Authors: Yuka Torii, Hiroshi Yagasaki, Hidenori Tanaka, Seiji Mizuno, Nobuhiro Nishio, Hideki Muramatsu, Asahito Hama, Yoshiyuki Takahashi, Seiji Kojima

Published in: International Journal of Hematology | Issue 2/2009

Abstract

Kabuki syndrome (KS) is often associated with autoimmune abnormalities, such as idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, leukoplakia and thyroiditis, as well as congenital anomalies. We herein present a KS patient with refractory ITP who achieved durable and complete remission in response to a total of four once-monthly infusions of rituximab. KS patients are often more susceptible to infection, so splenectomy should be avoided. Therefore, rituximab therapy is an alternative option for KS patients with ITP who fail to respond to first-line therapy.

Niikawa N, Matsuura N, Fukushima Y, et al. Kabuki make-up syndrome: a syndrome of mental retardation, unusual faces, large end protruding ears, and postnatal growth deficiency. J Pediatr. 1981;99:565–9.CrossRefPubMed

Kuroki Y, Suzuki Y, Chyo H, et al. A new malformation syndrome of long palpebral fissures, large ears, depressed nasal tip, and skeletal anomalies associated with postnatal dwarfism and mental retardation. J Pediatr. 1981;99:570–3.CrossRefPubMed

Niikawa N, Kuroki Y, Kajii T, et al. Kabuki make-up (Niikawa–Kuroki) syndrome: a study of 62 patients. Am J Med Genet. 1988;31:565–89.CrossRefPubMed

Kawame H, Hannibal MC, Hudgins L, et al. Phenotypic spectrum and management issues in Kabuki syndromes. J Pediatr. 1999;134:480–5.CrossRefPubMed

Hoffman JD, Ciprero KL, Sullivan KE, et al. Immune abnormalities are a frequent manifestation of Kabuki syndrome. Am J Med Genet. 2005;135A:278–81.CrossRef

Ming JE, Russell KL, McDonald-McGinn DM, et al. Autoimmune disorders in Kabuki syndrome. Am J Med Genet. 2005;132A:260–2.CrossRefPubMed

Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952–7.CrossRefPubMed

Bennett CM, Rogers ZR, Kinnamon DD, et al. Prospective phase 1/2 study of rituximab in children and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107:2639–42.CrossRefPubMedPubMedCentral

Wang J, Wiley JM, Luddy R, et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr. 2005;146:217–21.CrossRefPubMed

10.

Zaja F, Battista ML, Pirrotta MT, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Hematologica. 2008;93:930–3.CrossRef

11.

Provan D, Butler T, Evangelista ML, et al. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haemotologica. 2007;92:1695–8.CrossRef

12.

Stasi R, Stipa E, Forte V, et al. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood. 2002;99:3872–3.CrossRefPubMed

13.

Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease: the immune complex decoy hypothesis. Nat Clin Pract Rheumatol. 2007;3:86–95.CrossRefPubMed

14.

Olsson B, Andersson PO, Jernås M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9:1123–4.CrossRefPubMed

15.

Tokunaga M, Fujii K, Saito K, et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology. 2005;44:176–82.CrossRefPubMed

16.

Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110:2924–30.CrossRefPubMed

Title: Successful treatment with rituximab of refractory idiopathic thrombocytopenic purpura in a patient with Kabuki syndrome
Authors: Yuka Torii
Hiroshi Yagasaki
Hidenori Tanaka
Seiji Mizuno
Nobuhiro Nishio
Hideki Muramatsu
Asahito Hama
Yoshiyuki Takahashi
Seiji Kojima
Publication date: 01-09-2009
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 2/2009
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-009-0387-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Extracellular NM23-H1 protein inhibits the survival of primary cultured normal human peripheral blood mononuclear cells and activates the cytokine production

Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors

Differential diagnosis and treatment of primary, cutaneous, anaplastic large cell lymphoma: not always an easy task

Bilateral pulmonary nodules as a manifestation of primary pulmonary T-cell lymphoma

Multiple myeloma presenting with acquired factor VIII inhibitor

Increased serum levels of matrix metalloproteinase-9 in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer